A new DNA-based therapy could cut cholesterol nearly in half—without relying on statins or causing side effects.

Researchers have developed a DNA-based therapy that targets the PCSK9 gene to lower cholesterol naturally. Using polypurine ...

With Eli Lilly's recent acquisition of Verve Therapeutics and its PCSK9 candidate, delve into what the target represents.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced plans to present new research from ...

Researchers have unveiled a new DNA-based therapy that silences the PCSK9 gene to lower cholesterol without statin side effects. Early results show dramatic reductions in cholesterol levels, offering ...

Deepak L. Bhatt, MD, MPH: Speaking of PCSK9 inhibitors, let’s turn back to Dr Budoff. I was going to say this is a new class of medicine. They’re not that new anymore but are still exciting. Can you ...

Scientists have developed a breakthrough therapy that could revolutionise the treatment of high cholesterol, which currently ...

Outcomes-based pricing arrangements for pharmaceuticals are increasingly popular. In this piece, we discuss the impact of the outcomes-based pricing arrangements proposed by Amgen on the pricing of ...

Richa Munjal considers the current landscape for PCSK9 inhibitors and whether there is a brighter future on the horizon for this class of drugs. The promise of a new era of cholesterol management, ...

The quest to inhibit the cholesterol-related enzyme PCSK9 has produced two high-profile drugs and a massive patent battle between their makers. Now a group of scientists in Europe, along with the ...

New York, USA, Feb. 17, 2025 (GLOBE NEWSWIRE) -- PCSK9 Inhibitors Market Anticipate to Accelerate in the Coming 10 Years Owing to the Increasing Demand for Innovative Cholesterol-Lowering Drugs | ...

Systemic administration of anti-PCSK9 antibodies induces dramatic reductions in LDL-cholesterol levels, and the effect of this therapy on LDL-receptor activity seems to be additive to that of statin ...